REGENXBIO Inc.

NasdaqGS:RGNX 주식 리포트

시가총액: US$563.1m

REGENXBIO 향후 성장

Future 기준 점검 2/6

REGENXBIO (는) 각각 연간 49% 및 34.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 54.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -213.6% 로 예상됩니다.

핵심 정보

49.0%

이익 성장률

54.17%

EPS 성장률

Biotechs 이익 성장29.0%
매출 성장률34.9%
향후 자기자본이익률-213.58%
애널리스트 커버리지

Good

마지막 업데이트25 Aug 2026

최근 향후 성장 업데이트

Recent updates

Seeking Alpha • Aug 25

Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity

Summary Regenxbio is rated a 'risky buy' due to high volatility, regulatory setbacks, and significant near-term catalysts. RGNX faces a clinical hold on RGX-121 for Hunter Syndrome, complicating milestone payments and royalty streams, but maintains sufficient cash runway into Q4 2027. Pivotal data for the AbbVie-partnered eye disease program and BLA submission for RGX-202 in DMD represent major binary catalysts by year-end and 2027. RGNX offers rare exposure to late-stage gene therapy assets in multi-billion dollar markets, but bankruptcy risk remains if the pipeline fails. Read the full article on Seeking Alpha
내러티브 업데이트 • Aug 08

RGNX: Hunter Syndrome Refiling Plans Will Drive Future Upside Potential

Analysts have reduced the updated fair value estimate for REGENXBIO stock to about $45.54 from roughly $51.93. The change reflects a higher discount rate and mixed price target changes across the Street, which weigh regulatory uncertainty against potential upside from the gene therapy pipeline.
내러티브 업데이트 • Jun 15

RGNX: Future Duchenne Regulatory Outcomes Will Test Gene Therapy Bullish Thesis

Narrative Update on REGENXBIO The analyst price target for REGENXBIO in this framework moves from $12.00 to $10.00 as analysts factor in recent target cuts tied to a higher projected share count and continued regulatory uncertainty around RGX-202 in Duchenne muscular dystrophy. At the same time, they acknowledge encouraging functional data and a higher assumed profit margin.
내러티브 업데이트 • Jun 01

RGNX: AFFINITY DUCHENNE Data Will Shape Future Regulatory And Share Price Upside

Analysts have trimmed the implied fair value on REGENXBIO stock from about $29.75 to roughly $24.18. This reflects a cluster of lower Street price targets in the $12 to $42 range as they factor in a higher discount rate, updated views on RGX-202 regulatory uncertainty, and revised expectations for revenue growth, profit margins, and future P/E.
내러티브 업데이트 • Apr 26

RGNX: Future Gene Therapy Milestones Will Test Regulatory Risk And Support Bullish Reassessment

REGENXBIO's consensus analyst price target has been revised lower, with cuts ranging from about $1 to $12 as analysts factor in updated clinical timelines, recent FDA commentary around RGX-121 and the approach to rare disease, as well as upcoming pivotal readouts for key gene therapy programs. Analyst Commentary Recent research updates show that while several firms still carry positive ratings on REGENXBIO, they have been trimming price targets and highlighting a more cautious setup around regulatory risk, clinical execution, and timelines for key programs.
내러티브 업데이트 • Apr 11

RGNX: Future Pivotal Gene Therapy Readouts Will Drive Bullish Reassessment

Analysts have nudged their average price target for REGENXBIO slightly lower to reflect recent target cuts across firms, while still highlighting upcoming regulatory updates and pivotal readouts in Duchenne muscular dystrophy and wet age related macular degeneration as key drivers for their updated views. Analyst Commentary Recent research updates show that while upcoming data and regulatory milestones remain central to the REGENXBIO story, several price targets have been adjusted lower following the latest quarterly results and clinical updates.
내러티브 업데이트 • Mar 28

RGNX: Future Gene Therapy Milestones Will Drive Reassessment Despite Regulatory Uncertainty

Analysts have nudged their blended price target for REGENXBIO modestly lower by a few dollars to reflect recent reductions in firm level targets, while still pointing to upcoming regulatory updates and pivotal readouts across programs like RGX-202 and ABBV-RGX-314 as key factors in their outlook. Analyst Commentary Street research around REGENXBIO has tilted more cautious in recent weeks, with several price targets adjusted lower following the latest quarterly update, recent regulatory news and evolving views on the company’s gene therapy portfolio.
내러티브 업데이트 • Mar 12

RGNX: Future Gene Therapy Readouts Will Drive Reassessment Despite Regulatory Setbacks

Analysts have trimmed their average price targets on REGENXBIO, with cuts such as $32 to $30, $45 to $42 and $18 to $17. These changes reflect updated assumptions for slightly lower revenue growth and profit margins, partly offset by a modestly lower discount rate and a higher future P/E multiple.
내러티브 업데이트 • Feb 26

RGNX: Regulatory Resolution And Gene Therapy Data Will Drive Reassessment

Analysts have trimmed their price targets on REGENXBIO by up to $12, reflecting updated views on RGX-121 related regulatory uncertainty and revised assumptions for the discount rate, revenue growth, profit margin and future P/E, while the central fair value estimate remains at $12.00. Analyst Commentary Recent research updates around REGENXBIO have centered on RGX-121 and the regulatory commentary that investors are trying to interpret.
내러티브 업데이트 • Feb 11

RGNX: Clinical Hold Setbacks Will Refocus Attention On Upcoming Pivotal Data

Analysts have trimmed their fair value estimate for REGENXBIO to $12.00 from $14.00, citing a reset in price targets across the Street following clinical updates. The revised estimate still reflects higher modeled revenue growth and a lower future P/E multiple in their assumptions.
분석 기사 • Feb 06

REGENXBIO Inc. (NASDAQ:RGNX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough

REGENXBIO Inc. ( NASDAQ:RGNX ) shareholders won't be pleased to see that the share price has had a very rough month...
분석 기사 • Jan 29

Is REGENXBIO (NASDAQ:RGNX) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Dec 23

REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

REGENXBIO Inc. ( NASDAQ:RGNX ) shares have continued their recent momentum with a 27% gain in the last month alone. The...
분석 기사 • Oct 09

REGENXBIO Inc. (NASDAQ:RGNX) Held Back By Insufficient Growth Even After Shares Climb 29%

REGENXBIO Inc. ( NASDAQ:RGNX ) shares have continued their recent momentum with a 29% gain in the last month alone...
분석 기사 • Oct 03

Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Aug 12

Investors Don't See Light At End Of REGENXBIO Inc.'s (NASDAQ:RGNX) Tunnel

NasdaqGS:RGNX 1 Year Share Price vs Fair Value Explore REGENXBIO's Fair Values from the Community and select yours With...
내러티브 업데이트 • Aug 08

Gene Therapy Breakthroughs Will Unlock Expanding Future Markets

Analysts have revised REGENXBIO’s price target downward to $29.75, reflecting heightened sector scrutiny after competitor safety issues but maintaining confidence in RGX-202’s differentiated immune suppression strategy and clinical outlook. Analyst Commentary Safety issues with a competitor's product (Sarepta's Elevidys) have renewed focus on immune prophylaxis, highlighting Regenxbio's proactive approach to immune suppression with RGX-202.
분석 기사 • May 15

REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next

It's shaping up to be a tough period for REGENXBIO Inc. ( NASDAQ:RGNX ), which a week ago released some disappointing...
분석 기사 • May 01

REGENXBIO Inc. (NASDAQ:RGNX) Shares Fly 34% But Investors Aren't Buying For Growth

REGENXBIO Inc. ( NASDAQ:RGNX ) shareholders would be excited to see that the share price has had a great month, posting...
분석 기사 • Apr 24

Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
User avatar
새로운 내러티브 • Mar 30

FDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline

Strategic partnerships and FDA approvals drive potential revenue growth through new market penetrations and milestone payments.
Seeking Alpha • Mar 26

5 Reasons To Buy Regenxbio Right Now

Summary Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, with potential for the EV to turn negative once upcoming scheduled/milestone payments and royalties come in. RGNX benefits from strategic partnerships, including $110M from Nippon Shinyaku and $200M from AbbVie, plus potential higher royalties from Novartis. Technically speaking, the stock is shifting from bearish to bullish, with significant upside potential and positive price target trends from multiple analysts. RGNX is a prime buyout candidate, with AbbVie as a likely bidder, supported by several other potential suitors in the biotech and pharma sectors that are active/interested in Gene Therapy. Read the full article on Seeking Alpha
분석 기사 • Mar 04

The Market Doesn't Like What It Sees From REGENXBIO Inc.'s (NASDAQ:RGNX) Revenues Yet As Shares Tumble 27%

To the annoyance of some shareholders, REGENXBIO Inc. ( NASDAQ:RGNX ) shares are down a considerable 27% in the last...
Seeking Alpha • Jan 15

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Summary Regenxbio Inc. remains undervalued despite its cutting-edge AAV gene therapy technology and promising assets like RGX-314 for wet AMD and RGX-121 for MPS II. RGX-314, partnered with AbbVie, targets wet AMD with global regulatory submissions expected in H1 2026; RGX-121 has a rolling BLA submission expected to complete in Q1 2025. Financially, RGNX has a market cap of $344mn and a cash balance of $279mn, bolstered by a recent $110mn upfront fee from Nippon Shinyaku. Despite historical underperformance, I remain hopeful, banking on the durability of their wet AMD treatment and will continue buying at dips, giving RGNX stock two more years. Read the full article on Seeking Alpha
분석 기사 • Dec 28

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive

Unfortunately for some shareholders, the REGENXBIO Inc. ( NASDAQ:RGNX ) share price has dived 26% in the last thirty...
Seeking Alpha • Oct 31

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Summary Positive updated long-term results from phase I/II/III CAMPSITE study using RGX-121 for the treatment of patients with MPS II. Rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected any day now in Q4 of 2024. The global Hunter Syndrome treatment market is expected to reach $1.78 billion by 2030. RGX-202 for the treatment of patients with DMD and ABBV-RGX-314 for treatment of patients with diabetic retinopathy are other programs in pipeline; Late-stage studies starting Q4 of 2024 and 1st half 2025 respectively. Read the full article on Seeking Alpha
분석 기사 • Sep 12

Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Aug 06

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

Summary Regenxbio Inc.'s rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected in Q3 of 2024. Additional results from the phase 1/2/3 CAMPSIITE study, using RGX-121 for the treatment of patients with MPS II, expected in the 2nd half of 2024. Initiation of a pivotal study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q4 of 2024. Subretinal delivery of ABBV-RGX-314 for the treatment of patients with Wet-AMD is ongoing; Two studies being done are ATMOSPHERE and ASCENT and regulatory submissions U.S. And EU on track for 1st half of 2026. Read the full article on Seeking Alpha

이익 및 매출 성장 예측

NasdaqGS:RGNX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/2028365-117N/A-1186
12/31/2027217-200N/A-2189
12/31/2026168-176N/A-2569
6/30/2026174-196-250-247N/A
3/31/202688-290-236-234N/A
12/31/2025170-194-126-124N/A
9/30/2025161-178-106-103N/A
6/30/2025156-176-91-88N/A
3/31/2025157-158-87-84N/A
12/31/202483-227-176-173N/A
9/30/202484-239-185-182N/A
6/30/202489-241-195-191N/A
3/31/202487-260-199-193N/A
12/31/202390-263-228-218N/A
9/30/202399-261-231-217N/A
6/30/202397-274-236-218N/A
3/31/2023110-270-257-232N/A
12/31/2022113-280-238-207N/A
9/30/202248074134173N/A
6/30/202248491128181N/A
3/31/2022474101143207N/A
12/31/2021470128135219N/A
9/30/202193-212-166-83N/A
6/30/2021161-145-147-77N/A
3/31/2021156-121-116-63N/A
12/31/2020155-111-81-54N/A
9/30/2020145-91-134-119N/A
6/30/202061-135-123-112N/A
3/31/202052-103N/A-114N/A
12/31/201935-95N/A-108N/A
9/30/201964-64N/A-86N/A
6/30/201955-49N/A-77N/A
3/31/201987-37N/A17N/A
12/31/2018219100N/A105N/A
9/30/201818080N/A95N/A
6/30/201817678N/A97N/A
3/31/201814253N/A18N/A
12/31/201710-73N/A-58N/A
9/30/201710-77N/A-65N/A
6/30/20179-74N/A-59N/A
3/31/20175-74N/A-58N/A
12/31/20165-63N/A-49N/A
9/30/20167-49N/A-33N/A
6/30/20168-38N/A-29N/A
3/31/20167-32N/A-29N/A
12/31/20158-24N/A-23N/A
9/30/20154-21N/A-18N/A

애널리스트 향후 성장 전망

수입 대 저축률: RGNX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: RGNX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: RGNX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: RGNX 의 수익(연간 34.9%)이 US 시장(연간 13.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: RGNX 의 수익(연간 34.9%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: RGNX는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/09/13 09:46
종가2026/09/11 00:00
수익2026/06/30
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

REGENXBIO Inc.는 24명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Brian SkorneyBaird
Huidong WangBarclays
Eliana MerleBarclays